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Abstract
Objective: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertusiss (Tdap) vaccine is 
recommended during each pregnancy, regardless of prior receipt. Data on reactogenicity and 
immunogenicity, particularly after repeated Tdap, are limited. We compared local injection-site 
and systemic reactions and serologic response following Tdap in (1) pregnant and nonpregnant 
women and (2) pregnant women by self-reported prior Tdap receipt.
Study design: Pregnant women (gestational age 20–34 weeks) and nonpregnant women 
receiving Tdap were enrolled in this observational study. Injection-site and systemic reactions 
were assessed for one week post-vaccination. Pertussis toxin, filamentous hemagglutinin, 
pertactin, fimbriae, tetanus and diphtheria specific IgG antibody titers were determined by 
standardized enzyme-linked immunosorbent assay at baseline and 28 days post-vaccination. 
Reactogenicity and serologic responses were compared by pregnancy status, and within pregnant 
women by self-reported prior Tdap receipt.
☆Data presented at: The Society of Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting, Atlanta GA, February 2016 and to the 
Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), Atlanta, GA, June 2016.
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Results: 374 pregnant and 225 nonpregnant women were vaccinated. Severe local or systemic 
reactions or “any” fever were uncommon (≤3% for both groups). Moderate/severe injection-site 
pain was significantly higher in pregnant (17.9%) versus nonpregnant (11.1%) women, but did not 
prompt a healthcare visit. Proportions of other moderate/severe or any severe reactions were not 
significantly higher in pregnant compared to nonpregnant women. Moderate/severe (including 
pain) and severe reactions were not significantly higher in pregnant women receiving repeat versus 
first-time Tdap. Antibody titers increased from baseline to post-vaccination for all vaccine 
antigens in pregnant and nonpregnant women; postvaccination titers against pertussis toxin and 
filamentous hemagglutinin were significantly higher in nonpregnant versus pregnant women (p < 
0.01).
Conclusion: Tdap was well-tolerated in pregnant and nonpregnant women. Pregnant women 
were more likely to report moderate/severe pain at the Tdap injection-site compared with 
nonpregnant women, but did not necessitate medical visits. Prior Tdap receipt did not increase 
occurrence of moderate/severe local or systemic reactions in pregnant women. Serologic responses 
to all vaccine antigens were robust.
Abstract
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1. Introduction
In 2012 the Centers for Disease Control and Prevention (CDC) Advisory Committee on 
Immunization Practices (ACIP) recommended that pregnant women receive adult tetanus 
toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) during each 
pregnancy to protect their infants against pertussis via transplacental antibody transfer [1]. 
Available Tdap safety data were reassuring, but Tdap had not been extensively studied in 
pregnant women pre-licensure. Monitoring Tdap safety during pregnancy is a public health 
priority, particularly following repeated Tdap doses [1,2]. To complement CDC’s other 
maternal Tdap safety monitoring efforts, we conducted an observational study of pregnant 
women receiving Tdap vaccine.
Our primary objective was to compare local injection-site and systemic reactions following 
Tdap vaccination in pregnant women with nonpregnant women serving as controls [1,3,4]. 
Nonpregnant women served as the comparison group since there were prior data supporting 
the safety of Tdap in nonpregnant adults [1,3,4]. We hypothesized that the proportion of 
pregnant women with moderate/severe injection-site pain would not be higher than the 
proportion of nonpregnant women. A secondary objective was to compare reaction profiles 
between pregnant women receiving their first Tdap dose and those who reported prior Tdap 
receipt. We also explored cytokine levels in sera of women with and without severe reactions 
after Tdap. In addition, immune responses to all Tdap vaccine components at baseline and 
28 days post-vaccination were compared in pregnant and nonpregnant women.
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2. Materials and methods
2.1. Study design
This was a prospective, observational, cohort study conducted at two CDC-funded Clinical 
Immunization Safety Assessment (CISA) centers, Vanderbilt University Medical Center and 
Duke University Health System. The study protocol was approved by the institutional review 
boards at each study site and the CDC and registered at ClinicalTrials.gov (NCT02209623).
Pregnant women aged 18–45 years between 20 weeks 0 days and 33 weeks 6 days gestation, 
intending to receive 6 dap as part of standard ACIP guidelines, with a singleton pregnancy, 
English or Spanish literate, and with intention to be available throughout the study period 
were enrolled (see Supplemental Tables 1 and 2 for detailed eligibility criteria). In order to 
assess repeated Tdap exposure, women with prior Tdap vaccination were preferentially 
recruited.
Supplementary data associated with this article can be found, in the online version, at https://
doi.org/10.1016/j.vaccine.2018.07.012 .
After written informed consent was obtained, data regarding race, ethnicity, medical history, 
obstetric history, and current pregnancy status were collected. Prior Tdap, tetanus and 
diphtheria toxoid (Td) or tetanus toxoid (TT) vaccination history was solicited by self-report 
and verified, to the extent possible, by confirmation within each health system’s electronic 
medical record and/or state immunization information systems. Following baseline blood 
sampling, a single 0.5 mL intramuscular (IM) dose of either US-licensed Tdap (Adacel® or 
Boostrix® depending on clinical supply) was administered during routine prenatal care.
Nonpregnant women aged 18–45 years were recruited with similar eligibility criteria 
(Supplemental Tables 1 and 2). Prior receipt of Tdap was permitted in nonpregnant women 
as part of this research study. Vaccine manufacturer and lot number were recorded for all 
participants.
2.2. Vaccines
The Tdap Adacel® vaccine contained: 5 Limit of Flocculation units (Lf) tetanus toxoid, 2 Lf 
diphtheria toxoid, and acellular pertussis antigens [2.5 mcg detoxified pertussis toxin (PT), 5 
mcg filamentous hemagglutinin (FHA), 3 mcg pertactin (PRN), 5 mcg fimbriae types 2 and 
3 (FIM)] [3]. The Tdap Boostrix® vaccine contained 5 Lf of tetanus toxoid, 2.5 Lf diphtheria 
toxoid, 8 mcg inactivated PT, 8 mcg FHA, and 2.5 mcg PRN [4].
2.3. Safety assessments
To monitor the safety profile after vaccination, all study participants were given a digital oral 
thermometer, ruler, and memory aid to record local and systemic reactions and other adverse 
events after vaccination. Subjects were observed in the clinic for 20 min post-vaccination. 
With Day 0 serving as the day of vaccination, participants were followed through Day 7 for 
symptoms of reactogenicity based on “worst” symptoms each day. Local reactions assessed 
included pain, tenderness, induration/swelling, and erythema [5–7]. Systemic reactions 
assessed included temperature (obtained around the same time each evening), malaise, body 
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aches (myalgia), headache, and feverishness [3–5,7]. Reactions were graded as mild, 
moderate, or severe (Supplemental Tables 3 and 4). Adverse events (AE) and serious adverse 
events (SAEs) were defined in accordance with the U.S. Food and Drug Administration [8]. 
Participants were contacted on study days 1–2 and 7–9 to review reactogenicity data and to 
assess for any AEs, SAEs, or concomitant medications. Any participant with severe local or 
systemic reactions within 7 days after vaccination was evaluated in the clinic within 72 h 
and an additional blood sample was obtained for cytokine assays (“supplemental visit”). A 
subject without any systemic reactions, or only mild injection-site reaction, within the same 
time frame, was recruited to serve as a control (Supplemental Tables 3 and 4).
2.4. Immunogenicity and cytokine assessments
Participants returned at approximately 28 days post-vaccination to obtain any new medical 
information and blood sample collection. For nonpregnant women, study participation ended 
with the day 28 visit. Data regarding birth outcomes and infant follow-up at 3 and 6 months 
of life were subsequently collected among pregnant subjects and their infants (data to be 
described in a separate report).
Pre- and post-Tdap vaccine immune responses were measured using an established enzyme-
linked immunosorbent assay (ELISA) assay for serum Immunoglobulin G (IgG) to PT, 
FHA, PRN, and FIM [9]. Tetanus and diphtheria toxoid IgG levels were measured using a 
commercial standardized ELISA assay (Abcam; Cambridge, MA). Samples that had tetanus 
or diphtheria antibody levels above the upper limit of the assay were diluted until they were 
in range; each reported value for diphtheria and tetanus is the mean of ≥2 replicate assays.
For subjects with severe reactions and their controls, inflammatory cytokines were measured 
using the Mesoscale Discovery platform [10] with a dedicated SECTOR 2400 Imager. 
Cytokines studied included; Interleukin (lL)-5, 1L-6, 1L-8, 1L-10, and Tumor necrosis 
factor alpha (TNF-a). Cytokine levels, at the time of reaction, were compared in the same 
individual at the pre- and post-vaccination (28 days after vaccination) time periods and were 
compared with levels in controls by pregnancy status and study location.
2.5. Statistical analysis
Descriptive analysis was performed. Symptoms of reactogenicity occurring from Days 0 to 7 
were compared between pregnant and nonpregnant women. Moderate/severe injection-site 
pain was selected as primary outcome for the purpose of sample size and power calculation 
although all local and systemic reactions were analyzed. The primary null hypothesis was 
that the proportion of pregnant women with moderate/severe pain would be higher than 
nonpregnant women with 10% as the maximum clinically acceptable difference, assuming 
the proportion of moderate/ severe pain in nonpregnant women was less or equal to 25%. 
The sample size of 375 pregnant and 225 nonpregnant women, including a projected 5% 
drop-out, was designed to have at least 85% power to assert non-inferiority. For each 
reactogenicity outcome, the one-sided 95% confidence interval (CI) was calculated for the 
difference (delta) in the proportion in the pregnant women minus proportion in nonpregnant 
women. For the moderate/severe pain outcome, the one-sided 95%C1 of delta, adjusting for 
ethnicity and race, was also calculated using bootstrapping method [11]. The pre-specified 
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delta of 10% for moderate/severe or 5% for severe out-come was used to compare with each 
reaction’s upper bound to decide whether a non-inferiority test was significant. 1f the upper 
limit was greater than the delta, the null hypothesis of inferiority could not be rejected at the 
5% significance level [12]. Proportions of moderate/severe and severe reactions were also 
compared between pregnant women with and without previous Tdap receipt. We did not 
adjust for multiple comparisons in these analyses.
Geometric mean titers (GMTs) of antibody were calculated for all the pertussis, diphtheria, 
and tetanus antigens along with 95% C1s. Comparisons between pregnant and nonpregnant 
women and pregnant women with or without previous Tdap were performed by T-test. 
Paired T-tests were conducted for comparisons of pre- and post-vaccination titers, excluding 
F1M serology for those who received Boostrix® since this vaccine does not contain F1M 
[4].
Wilcoxon signed rank tests were conducted for pairwise comparisons among Day 0 visit, the 
supplemental visit, and the Day 28 visit for the cases with the severe reactions and between 
matched cases and controls for cytokine results at similar times due to the concern of the 
small sample size. 1f a cytokine value was below limit of detection (LOD), half of LOD was 
assigned as standard for the laboratory. All tests were two-sided except non-inferiority test 
and p value <0.05 was considered as statistical significance. All analyses were performed 
using R version 3.2.2.
3. Results
From July 2014 to July 2015, 374 pregnant women and 225 nonpregnant women were 
enrolled. Demographic and clinical characteristics of the study participants are described in 
Table 1. The median age at enrollment was similar between pregnant and nonpregnant 
women (28.9 years vs. 28.3 years). Among all pregnant women, median gestational age at 
enrollment was 29.2 weeks with 88.8% non-Hispanic ethnicity and 62.7% white and 32.2% 
black race. Among nonpregnant women, 95.1% reported non-Hispanic ethnicity and 78.5% 
white and 12.6% black race. Prior Tdap receipt was reported by over half of pregnant 
(52.9%) and nonpregnant (64.5%) women. Pregnant subjects primarily received Adacel® 
(Vanderbilt 98.4%; Duke 95.2%), while 100% of nonpregnant subjects at Vanderbilt and 
77.3% at Duke received Adacel®. All remaining subjects received Boostrix® except four 
who did not have clear documentation of the specific product received.
3.1. Safety
Safety assessments comparing moderate, severe, and moderate/severe local and systemic 
reactions for pregnant and nonpregnant women are shown in Table 2. Compared with 
nonpregnant women, pregnant women were more likely to experience moderate/severe pain 
at the injection site (17.9% vs. 11.1% in pregnant and nonpregnant women, respectively), 
but the occurrence of other moderate/severe and all severe local and systemic reactions 
assessed were not different between pregnant and nonpregnant women. After adjusting for 
race and ethnicity in those reporting moderate/severe pain, the upper bound of 95% CI of the 
difference of proportion between pregnant and nonpregnant groups was 11.9%, indicating 
that the difference persisted. Severe local and systemic reactions or fever were uncommon 
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(≤3%) among all participants and no woman sought medical care for any reactions. Only 
two pregnant and five nonpregnant women reported fever (≥38 °C) after vaccination (Table 
2). The most commonly occurring mild reactions among pregnant subjects were: injection-
site tenderness (61.7%), pain (50.0%), and malaise (23.9%) and among nonpregnant subjects 
were: tenderness (73.5%), pain (66.4%) and headache (30.0%). When examining symptoms 
by post-vaccination day, the highest proportions of moderate/severe pain were reported on 
the first day after vaccination. There were no adverse events during the 20-minute post-
vaccination observation period and no serious adverse events for 28 days post-vaccination.
3.2. First Tdap exposure vs. repeat Tdap in pregnant women
In evaluating reactogenicity by prior Tdap receipt in pregnant women, 198 of 301 women 
self-reported prior Tdap receipt, while 74 pregnant women could not recall their Tdap 
history. Eight pregnant women in the study had more than one Tdap within the past 12 
months and none experienced severe reactions or fever. Among those with documented prior 
Tdap receipt, 98 women had received prior Tdap in the past 1–5 years. Subjects (73) with 
unknown prior Tdap vaccination status were excluded from this portion of the analysis, but 
were notable for higher proportion of Hispanic ethnicity compared to women with known 
prior Tdap (22% vs. 6%). The proportions of pregnant women with moderate/severe 
reactions were not higher among pregnant women receiving a repeat Tdap dose versus those 
receiving their first, Fig. 1. Specifically, moderate/severe pain (17.0% vs. 18.7%) was not 
significantly higher and non-inferiority criteria were also met for all other moderate/severe 
and severe local and systematic reactions.
3.3. Immunogenicity
Compared to baseline, post-vaccination geometric mean antibody titers (GMT) to all vaccine 
antigens were significantly higher in both pregnant and nonpregnant women regardless of 
prior Tdap receipt (Table 3 and Supplemental Table 5). Compared to pregnant women, 
nonpregnant women had significantly higher post-vaccination GMTs for PT, FHA, tetanus, 
and diphtheria, but not for the FIM or PRN. Among pregnant women, those who were 
previously vaccinated with Tdap had significantly higher baseline GMTs than those without 
prior Tdap; however, post-vaccination GMTs to FIM, PRN, and tetanus were significantly 
higher in the pregnant women without prior Tdap receipt. All women in the study achieved 
titers of ≥0.1 International Units/ mL, the correlate of protection for tetanus and diphtheria 
toxoids after Tdap [3,4].
3.4. Cytokines
A total of six cases of severe local or systemic reactions were identified and seen by study 
staff and matched with six controls. Among cases, five women had severe local reactions 
(induration and/or swelling), a single subject had severe systemic reaction with fever 
(102.4 °F), and one had both local and systemic reactions (fever 
(101.2 °F),bodyaches(myalgias), 70 mm induration and 30 mmery- thema). Of the six 
women with severe reactions, three had no prior Tdap recorded. Cytokines were measured 
for all women with severe reactions and their controls. The majority of the results for IL-5, 
IL-6, IL-8, IL-10, and TNFα were all close to the lower limit of detection at all times 
measured (Table 4). The cytokine levels measured in cases with severe reactions did not 
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differ among pre and post-vaccination or supplemental visit samples, meaning, no 
statistically significant differences were noted in cytokine levels obtained at any of the Day 
0, supplemental, or Day 28 visits.
4. Discussion
In our study, Tdap had a safety profile consistent with previous reports among nonpregnant 
[5,7,13] and pregnant persons [14–16]. Tdap was well-tolerated regardless of pregnancy 
status and prior Tdap receipt. Very few (≤3%) pregnant women who received a dose of Tdap 
vaccine reported severe reactions, and <1% of pregnant women reported any fever after 
vaccination. Contrary to our hypothesis, pregnant women were more likely to report 
moderate/severe pain at the Tdap injection-site compared with nonpregnant women; 
however, these symptoms did not necessitate medical visits. The frequency of pain reported 
among pregnant women was comparable to that previously reported in clinical trials for 
FDA licensure in nonpregnant persons [3]. Physical, hormonal, and psychological changes 
intrinsic to pregnancy may alter analgesic experience and perception [17]. One small study 
comparing pain between pregnant (n = 39) and nonpregnant (n = 22) women found 
increased, widespread, deep-tissue hypersensitivity during pregnancy [18]. In our study, 
similar proportions of other local reactions in pregnant versus nonpregnant women 
(including tenderness) were seen, suggesting non-biological factors may also account for the 
increased moderate/severe pain finding. Munoz reported similar proportions of injection-site 
pain (not graded) after Tdap in 26 pregnant and 12 nonpregnant women [13]. Fifty-one (of 
370) Thai women receiving Tdap during pregnancy reported moderate or severe local 
reaction, which is a higher rate than we observed [19]. While not compared with 
nonpregnant women, New Zealand researchers utilized telephone interviews at 48 h and four 
weeks after Tdap and influenza vaccination in 793 pregnant women, and noted similar low 
rates of severe pain (2.6%), severe swelling and erythema (0.4%), and fever (2.1%) [14].
Repeated doses of Td/TT were associated with increased moderate or severe reactions in 
older studies [7]. More recent studies assessing the safety of Tdap after Td/TT or repeat 
doses of Tdap, primarily in nonpregnant individuals, have not identified clinically important 
safety concerns. However, theoretical concerns exist that increased severe reactions could 
occur among pregnant women receiving repeated Tdap [1,7,20–22], especially among 
women with closely spaced pregnancies. We found no increase in moderate/severe or severe 
reactions in pregnant women who received prior Tdap, compared with those receiving Tdap 
for the first time. Our results are supported by a recent large retrospective cohort study, 
conducted through the Vaccine Safety Datalink (VSD), showing no difference in medically-
attended acute adverse events in mothers or adverse birth outcomes among pregnant women 
related to timing of Tdap since the prior tetanus-containing vaccine [23]. Further consistent 
reports from a Thai study showed no increase in AEs among 98 women receiving at least 
one additional dose of tetanus-containing vaccine during pregnancy [19]. However, Perry et 
al reported 24 of 737 (3%) women would not accept Tdap in a subsequent pregnancy due to 
a reaction occurring in her current pregnancy [24]. In addition, a recent Australian cohort 
study, in pregnant women receiving Tdap, and/or influenza vaccine suggested that local 
reactions were more common after Tdap in pregnant women with a history of prior Tdap 
receipt versus those receiving their first Tdap dose [15]. As women continue to receive 
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additional doses of Tdap in subsequent pregnancies, it will be important to continue to 
monitor for adverse events.
In our study, post-vaccination titers showed statistically significant rises to all vaccine 
antigens in both pregnant and nonpregnant subjects. However, both pre- and post-
vaccination antibody levels were lower among pregnant versus nonpregnant women. This 
finding has been inconsistently reported with other vaccine antigens, including Tdap and 
Influenza vaccines [13,25]. All women had seroprotective levels of antibody to diphtheria 
and tetanus toxoids after Tdap [3,4]. In the six women with severe reactions, systemic 
cytokines obtained immediately before and one month after vaccination were not 
statistically different from those obtained at the time of the severe adverse event and were 
not different than those seen in the control subjects.
Although we were able to prospectively follow 374 women receiving Tdap vaccination, our 
study has a few limitations, including differing racial and ethnic characteristics of women in 
the pregnant and nonpregnant groups. Yet, significant findings persisted after adjusting for 
race and ethnicity. If women with a previous Tdap had experienced a reaction after 
vaccination they may have been more reluctant to receive Tdap as part of their routine care, 
potentially biasing our results. We were also unable to confirm prior Tdap receipt for nearly 
70 subjects.
5. Conclusion
Our study provides a population of prospectively enrolled pregnant and nonpregnant women 
in the United States who received Tdap with comprehensive local and systemic reaction 
assessments. Our findings provide reassurance of the safety of Tdap in both pregnant and 
nonpregnant women, and in those with prior Tdap receipt. In addition, robust serologic 
responses in both pregnant and nonpregnant women were seen after Tdap vaccination.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Proportion of moderate/severe reactions among pregnant women with and without prior tdap 
receipt. Proportions of pregnant women with moderate/severe reactions among pregnant 
women receiving a repeat dose of Tdap versus those receiving their first dose. Error bars 
represent 95% confident intervals.
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Table 4
Summary of Cytokine Results between Cases with Severe Reaction and Controls.
Cytokine Cases, N = 6
Median
(mean ± STD)
Pg/mL
Controls, N = 6
Median
(mean ± STD)
Pg/mL
P
value
IL-6 Day 0 0.8 (0.9 ± 0.7) 0.9 (0.9 ± 0.6) 1.00
IL-6 Supplemental Visit 0.8 (1.1 ±0.8) 0.8 (1.0 ±0.8) 0.53
IL-6 Day 28 1.1 (1.0 ±0.5) 0.5 (0.7 ± 0.4)* 0.59
IL-8 Day 0 8.8 (14.1 ±13.1) 6.0 (6.8 ± 2.5) 0.06
IL-8 Supplemental Visit 9.6 (21.5 ±24.1) 7.0 (7.5 ±2.1) 0.40
IL-8 Day 28 11.1 (22.6 ±30.0) 5.0 (6.4 ± 2.6)* 0.06
IL-10 Day 0 0.4 (0.4 ±0.1) 0.4 (0.4 ± 0.2) 0.83
IL-10 Supplemental Visit 0.3 (0.7 ± 0.9) 0.3 (0.3 ±0.1) 0.42
IL-10-Day 28 0.3 (0.4 ±0.1) 0.4 (0.5 ± 0.3)* 0.59
TNF-α Day 0 0.4 (0.6 ± 0.4) 0.4 (0.5 ± 0.2) 0.37
TNF-α Supplemental Visit 0.8 (0.9 ± 0.5) 0.4 (0.5 ± 0.2) 0.20
TNF-α Day 28 0.8 (0.9 ± 0.4) 0.4 (0.5 ± 0.4)* 0.20
IL- 5 Day 0 0.3 (0.4 ± 0.2) 0.3 (0.3 ±0.1) 0.86
IL- 5 Supplemental Visit 0.5 (0.7 ± 0.6) 0.3 (0.3 ± 0.0) 0.18
IL- 5 Day 28 0.3 (0.3 ± 0.2) 0.3 (0.6 ± 0.7)* 1.00
IL: Interleukin. TNF: Tumor Necrosis Factor. Pg: picograms.
Day 0 represents serology drawn before vaccination. Supplemental Visit refers to the additional visit after vaccination with report of severe local or 
systemic reaction (or controls). Day 28 is 28 days after vaccination.
Information based on 1 Duke case (nonpregnant) and 5 Vanderbilt cases (3 nonpregnant and 2 pregnant).
One control subject did not have results for cytokines at Day 28;
*
“”values are based on 5 control samples instead of 6 controls.
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